VistaGen Therapeutics, Inc.
VTGN
$3.60
-$0.83-18.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -17.60% | -33.40% | -54.28% | -33.01% | 7.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.60% | -33.40% | -54.28% | -33.01% | 7.96% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -17.60% | -33.40% | -54.28% | -33.01% | 7.96% |
| SG&A Expenses | 2.69% | 7.89% | 21.48% | 30.03% | 34.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.42% | 54.10% | 65.65% | 53.21% | 27.00% |
| Operating Income | -43.58% | -56.33% | -69.51% | -55.86% | -27.44% |
| Income Before Tax | -57.33% | -68.04% | -75.12% | -47.50% | -11.50% |
| Income Tax Expenses | -100.00% | 600.00% | 75.00% | 128.57% | 128.57% |
| Earnings from Continuing Operations | -57.30% | -68.05% | -75.12% | -47.51% | -11.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.30% | -68.05% | -75.12% | -47.51% | -11.52% |
| EBIT | -43.58% | -56.33% | -69.51% | -55.86% | -27.44% |
| EBITDA | -43.62% | -56.45% | -69.71% | -56.02% | -27.51% |
| EPS Basic | -46.44% | -16.40% | 21.67% | 56.13% | 72.42% |
| Normalized Basic EPS | -46.51% | -16.41% | 21.65% | 56.13% | 72.43% |
| EPS Diluted | -46.44% | -16.40% | 21.67% | 56.13% | 72.42% |
| Normalized Diluted EPS | -46.51% | -16.41% | 21.65% | 56.13% | 72.43% |
| Average Basic Shares Outstanding | 7.27% | 24.15% | 59.80% | 127.10% | 285.39% |
| Average Diluted Shares Outstanding | 7.27% | 24.15% | 59.80% | 127.10% | 285.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |